XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT
on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility
of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.
Phase:
N/A
Details
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine